The Cluster ion spectrometry (CIS) experiment

…, J Cuvilo, C Martz, JL Médale, H Perrier… - The cluster and phoenix …, 1997 - Springer
… The time resolution of the instrument is sufficiently high to follow density or flux oscillations
at the gyrofrequency of H+ ions in a magnetic field of 10 nT or less. Such field strengths will be …

First multispacecraft ion measurements in and near the Earth's magnetosphere with the identical Cluster ion spectrometry (CIS) experiment

…, JL Medale, E Penou, H Perrier… - Annales …, 2001 - angeo.copernicus.org
On board the four Cluster spacecraft, the Cluster Ion Spectrometry (CIS) experiment measures
the full, three-dimensional ion distribution of the major magnetospheric ions (H + , He + , …

Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients

M Giovannini, JF Seitz, G Monges, H Perrier… - …, 1995 - thieme-connect.com
Background and Study Aims: Diagnosis of submucosal lesions, pancreatic tumors, and
mediastinal or celiac lymph nodes or masses is possible using endoscopic ultrasonography (EUS…

The discovery of rofecoxib,[MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2 inhibitor

…, GP O'Neill, M Ouellet, MD Percival, H Perrier… - Bioorganic & medicinal …, 1999 - Elsevier
… For example, 3, (X = 4-fluorine, entry a, Table 2), is more potent in the COX-1 assay than
entry b (X = H). This is generally true for other para-substituents such as halogens, methyl …

Slow-and tight-binding inhibitors of the 85-kDa human phospholipase A2

…, F Laliberte, F Ghomashchi, Z Wang, H Perrier… - Biochemistry, 1993 - ACS Publications
Revised Manuscript Received April 1, 1993 abstract: A trifluoromethyl ketone analogue of
arachidonic acid in which the COOH group is replaced with COCF3 (AACOCF3) was prepared …

Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and …

…, M Ouellet, D Patrick, MD Percival, H Perrier… - … of Pharmacology and …, 1999 - ASPET
The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX involved in
inflammation and that COX-1 is the major isoform responsible for the production of prostaglandins (…

[HTML][HTML] Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment …

…, F Meniai, C Peres, A Esparcieux, H Perrier… - European Journal of …, 2020 - Elsevier
Background Cancer patients are thought to have an increased risk of developing severe
Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, …

[HTML][HTML] BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced …

…, M Gilabert, E François, L Dahan, H Perrier… - Annals of oncology, 2012 - Elsevier
Background Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and
angiogenic pathways. A phase I trial demonstrated that the combination of gemcitabine and …

5‐lipoxygenase‐activating protein is an arachidonate binding protein

…, ME Cox, E Wong, S Charleson, H Perrier… - FEBS …, 1993 - Wiley Online Library
… rvFLAP600-9 for 48 h. FLAP was undetectable in the 100,000 xg supernatant fraction of
infected cells, suggesting that the protein is efficiently transferred to a membrane fraction when …

[HTML][HTML] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus …

…, H Naman, P Nouyrigat, S Oziel-Taieb, H Perrier… - Annals of oncology, 2013 - Elsevier
Background ML18147 evaluated continued bevacizumab with second-line chemotherapy
for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line …